Advertisement


Meena Moran, MD, on Ductal Carcinoma In Situ: Improving Local Control

2016 ASTRO Annual Meeting

Advertisement

Meena Moran, MD, of Yale University, discusses an analysis from 10 pooled academic institutions that showed a radiation boost after whole breast radiation therapy improves local control of this disease. (Abstract 324)



Related Videos

Lung Cancer

Thomas J. Lynch, Jr, MD, on Personalized Care and Radiation Oncology in Lung Cancer

Thomas J. Lynch, Jr, MD, of Massachusetts General Hospital, summarizes his keynote lecture on whether we are any closer to curing lung cancer with targeted treatments. (Keynote Address 2)

Issues in Oncology

Louis Harrison, MD, on Radiation Oncology and the Future of Health Care

Louis B. Harrison, MD, of the Moffitt Cancer Center, discusses radiation oncology in the context of personalized medicine, multidisciplinary care, new technology and applications, and the mandate to contain costs.

Prostate Cancer

Paul L. Nguyen, MD, on Prostate Cancer: High-Risk Disease, Brachytherapy, And Hormones

Paul L. Nguyen, MD, of the Dana-Farber Cancer Institute, summarizes a session he moderated, which included talks on local recurrence following brachytherapy, long-term PSA stability after the procedure, and androgen deprivation and high-dose radiotherapy. (Scientific Session 41)

Lung Cancer

Maria Werner-Wasik, MD, on Issues in Lung Toxicity

Maria Werner-Wasik, MD, of Thomas Jefferson University Hospital, summarizes a session she moderated on lung toxicity, including the impact of cardiac radiation, the risk of radiation to thoracic vertebral bodies, radiation pneumonitis, and upfront SBRT. (Scientific Session 39)

Prostate Cancer

Bradley R. Prestidge, MD, on Prostate Cancer: Initial Findings of NRG Oncology/RTOG 0232

Bradley R. Prestidge, MD, of Bon Secours VA Health System, summarizes his plenary lecture on this phase III trial comparing combined external beam radiation and transperineal interstitial permanent brachytherapy with brachytherapy alone for selected patients with intermediate-risk prostate cancer. (Plenary Lecture 1, Presentation 7)

Advertisement

Advertisement




Advertisement